Expression and in vitro function of anti-PD-L1 human antibody expressed in plant

被引:5
|
作者
Lee, Chae Eun [1 ]
Lee, Jeong Hwan [1 ]
Chung, Hyun Joo [1 ]
Lee, Da Won [1 ]
Lim, Jong Seok [1 ]
Kim, Kibum [3 ]
Kim, Jin Wook [4 ,5 ]
Lee, Yong Seong [4 ]
Kim, Kyung Soo [6 ]
Min, Hyun Jin [6 ]
Ko, Kisung [2 ,3 ]
Myung, Soon Chul [1 ,2 ]
机构
[1] Chung Ang Univ, Coll Med, Dept Urol, Seoul, South Korea
[2] Chung Ang Univ, Mol Biodesign Res Ctr, Seoul, South Korea
[3] Chung Ang Univ, Coll Med, Dept Med, Therapeut Prot Engn Lab, Seoul, South Korea
[4] Chung Ang Univ, Dept Urol, Gwangmyeong Hosp, Gyeonggi Do, South Korea
[5] Chung Ang Univ, Coll Med, Dept Med Informat, Seoul, South Korea
[6] Chung Ang Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Anti-PD-L1; antibodies; Avelumab; Immune system; Plant expression system; Therapeutic protein; VACCINES;
D O I
10.1007/s11816-023-00844-7
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Plants can be used to produce recombinant functional proteins such as antibodies and vaccines. In this study, transgenic plants were utilized to express anti-human programmed death ligand-1 (PD-L1) monoclonal antibodies (mAb(P) PD-L1) tagged with the endoplasmic reticulum retention motif KDEL. PCR and immunoblot analyses confirmed that mAb PD-L1 was expressed in transgenic plants. ELISA analysis confirmed the binding activity of mAb(P) PD-L1 to human prostate and urothelial cancer cell lines PC-3 and TCCSUP, respectively. Confocal imaging analysis demonstrated that mAb(P) PD-L1 had binding activity against human cancer cell lines similar to Avelumab (mAb(M) PD-L1). Confocal imaging analysis showed that the binding activity of mAb(P) PD-L1 to the human tonsil is comparable to mAb(M) PD-L1. These results suggest that mAb(P) PD-L1 shows functional binding activities for PD-L1(+) cancer cells. Hence, this study showed that tobacco plants can be used to produce functional anti-human PD-L1 mAbs.
引用
收藏
页码:531 / 539
页数:9
相关论文
共 50 条
  • [31] Radiation Recall Pneumonitis Induced by Anti-PD-L1 Monoclonal Antibody Durvalumab
    Adunse, J. U.
    Kalifa, M.
    Assaly, R. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [32] Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
    Ken Ogasawara
    Kathryn Newhall
    Stephen E. Maxwell
    Justine Dell’Aringa
    Vitalina Komashko
    Nurgul Kilavuz
    Richard Delarue
    Myron Czuczman
    Lars Sternas
    Shelonitda Rose
    C. L. Beach
    Steven Novick
    Simon Zhou
    Maria Palmisano
    Yan Li
    Clinical Pharmacokinetics, 2020, 59 : 217 - 227
  • [33] Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
    Qi, J.
    Gao, G. F.
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2017, 46 : S171 - S171
  • [34] Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
    Kefang Liu
    Shuguang Tan
    Yan Chai
    Danqing Chen
    Hao Song
    Catherine Wei-Hong Zhang
    Yi Shi
    Jun Liu
    Wenjie Tan
    Jianxin Lyu
    Shan Gao
    Jinghua Yan
    Jianxun Qi
    George F Gao
    Cell Research, 2017, 27 : 151 - 153
  • [35] Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (04) : 343 - 350
  • [36] Bilateral Optic Neuritis Secondary to Immune Etiology by anti-PD-L1 Antibody
    Vicente-Pascual, Mikel
    Molins-Rojas, Cristina
    Rosas-Soto, Katiuska
    Murata-Yonamine, Eleonor P.
    Vazquez-Justes, Daniel
    Purroy, Francisco
    Traveset-Maeso, Alicia
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2021, 41 (02) : E177 - E179
  • [37] Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
    Faiena, Izak
    Cummings, Amy L.
    Crosetti, Anna M.
    Pantuck, Allan J.
    Chamie, Karim
    Drakaki, Alexandra
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 209 - 215
  • [38] Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies
    Heskamp, Sandra
    Hobo, Willemijn
    Molkenboer-Kuenen, Janneke D. M.
    Olive, Daniel
    Oyen, Wim J. G.
    Dolstra, Harry
    Boerman, Otto C.
    CANCER RESEARCH, 2015, 75 (14) : 2928 - 2936
  • [39] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [40] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50